<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20230918041107&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;ff=20230918041107&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Mon, 18 Sep 2023 08:11:10 +0000</lastbuilddate>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714137/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4254-4255. doi: 10.1016/j.cell.2023.08.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714137/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37714137</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.025>10.1016/j.cell.2023.08.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714137</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Yasuyuki Hosono</dc:creator>
<dc:creator>Yashar S Niknafs</dc:creator>
<dc:creator>John R Prensner</dc:creator>
<dc:creator>Matthew K Iyer</dc:creator>
<dc:creator>Saravana M Dhanasekaran</dc:creator>
<dc:creator>Rohit Mehra</dc:creator>
<dc:creator>Sethuramasundaram Pitchiaya</dc:creator>
<dc:creator>Jean Tien</dc:creator>
<dc:creator>June Escara-Wilke</dc:creator>
<dc:creator>Anton Poliakov</dc:creator>
<dc:creator>Shih-Chun Chu</dc:creator>
<dc:creator>Sahal Saleh</dc:creator>
<dc:creator>Keerthana Sankar</dc:creator>
<dc:creator>Fengyun Su</dc:creator>
<dc:creator>Shuling Guo</dc:creator>
<dc:creator>Yuanyuan Qiao</dc:creator>
<dc:creator>Susan M Freier</dc:creator>
<dc:creator>Huynh-Hoa Bui</dc:creator>
<dc:creator>Xuhong Cao</dc:creator>
<dc:creator>Rohit Malik</dc:creator>
<dc:creator>Timothy M Johnson</dc:creator>
<dc:creator>David G Beer</dc:creator>
<dc:creator>Felix Y Feng</dc:creator>
<dc:creator>Weibin Zhou</dc:creator>
<dc:creator>Arul M Chinnaiyan</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA</dc:title>
<dc:identifier>pmid:37714137</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.025</dc:identifier>
</item>
<item>
<title>Orphan quality control shapes network dynamics and gene expression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4252-4253. doi: 10.1016/j.cell.2023.08.006.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37714136</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.006>10.1016/j.cell.2023.08.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714136</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Kevin G Mark</dc:creator>
<dc:creator>SriDurgaDevi Kolla</dc:creator>
<dc:creator>Jacob D Aguirre</dc:creator>
<dc:creator>Danielle M Garshott</dc:creator>
<dc:creator>Stefan Schmitt</dc:creator>
<dc:creator>Diane L Haakonsen</dc:creator>
<dc:creator>Christina Xu</dc:creator>
<dc:creator>Lukas Kater</dc:creator>
<dc:creator>Georg Kempf</dc:creator>
<dc:creator>Brenda Martínez-González</dc:creator>
<dc:creator>David Akopian</dc:creator>
<dc:creator>Stephanie K See</dc:creator>
<dc:creator>Nicolas H Thomä</dc:creator>
<dc:creator>Michael Rapé</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Orphan quality control shapes network dynamics and gene expression</dc:title>
<dc:identifier>pmid:37714136</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.006</dc:identifier>
</item>
<item>
<title>Modular pooled discovery of synthetic knockin sequences to program durable cell therapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>Chronic stimulation can cause T cell dysfunction and limit the efficacy of cellular immunotherapies. Improved methods are required to compare large numbers of synthetic knockin (KI) sequences to reprogram cell functions. Here, we developed modular pooled KI screening (ModPoKI), an adaptable platform for modular construction of DNA KI libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4216-4234.e33. doi: 10.1016/j.cell.2023.08.013.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Chronic stimulation can cause T cell dysfunction and limit the efficacy of cellular immunotherapies. Improved methods are required to compare large numbers of synthetic knockin (KI) sequences to reprogram cell functions. Here, we developed modular pooled KI screening (ModPoKI), an adaptable platform for modular construction of DNA KI libraries using barcoded multicistronic adaptors. We built two ModPoKI libraries of 100 transcription factors (TFs) and 129 natural and synthetic surface receptors (SRs). Over 30 ModPoKI screens across human TCR- and CAR-T cells in diverse conditions identified a transcription factor AP4 (TFAP4) construct that enhanced fitness of chronically stimulated CAR-T cells and anti-cancer function in vitro and in vivo. ModPoKI's modularity allowed us to generate an ∼10,000-member library of TF combinations. Non-viral KI of a combined BATF-TFAP4 polycistronic construct enhanced fitness. Overexpressed BATF and TFAP4 co-occupy and regulate key gene targets to reprogram T cell function. ModPoKI facilitates the discovery of complex gene constructs to program cellular functions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37714135</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.013>10.1016/j.cell.2023.08.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714135</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Franziska Blaeschke</dc:creator>
<dc:creator>Yan Yi Chen</dc:creator>
<dc:creator>Ryan Apathy</dc:creator>
<dc:creator>Bence Daniel</dc:creator>
<dc:creator>Andy Y Chen</dc:creator>
<dc:creator>Peixin Amy Chen</dc:creator>
<dc:creator>Katalin Sandor</dc:creator>
<dc:creator>Wenxi Zhang</dc:creator>
<dc:creator>Zhongmei Li</dc:creator>
<dc:creator>Cody T Mowery</dc:creator>
<dc:creator>Tori N Yamamoto</dc:creator>
<dc:creator>William A Nyberg</dc:creator>
<dc:creator>Angela To</dc:creator>
<dc:creator>Ruby Yu</dc:creator>
<dc:creator>Raymund Bueno</dc:creator>
<dc:creator>Min Cheol Kim</dc:creator>
<dc:creator>Ralf Schmidt</dc:creator>
<dc:creator>Daniel B Goodman</dc:creator>
<dc:creator>Tobias Feuchtinger</dc:creator>
<dc:creator>Justin Eyquem</dc:creator>
<dc:creator>Chun Jimmie Ye</dc:creator>
<dc:creator>Julia Carnevale</dc:creator>
<dc:creator>Ansuman T Satpathy</dc:creator>
<dc:creator>Eric Shifrut</dc:creator>
<dc:creator>Theodore L Roth</dc:creator>
<dc:creator>Alexander Marson</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Modular pooled discovery of synthetic knockin sequences to program durable cell therapies</dc:title>
<dc:identifier>pmid:37714135</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.013</dc:identifier>
</item>
<item>
<title>Complex effects of sequence variants on lipid levels and coronary artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>Many sequence variants have additive effects on blood lipid levels and, through that, on the risk of coronary artery disease (CAD). We show that variants also have non-additive effects and interact to affect lipid levels as well as affecting variance and correlations. Variance and correlation effects are often signatures of epistasis or gene-environmental interactions. These complex effects can translate into CAD risk. For example, Trp154Ter in FUT2 protects against CAD among subjects with the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4085-4099.e15. doi: 10.1016/j.cell.2023.08.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many sequence variants have additive effects on blood lipid levels and, through that, on the risk of coronary artery disease (CAD). We show that variants also have non-additive effects and interact to affect lipid levels as well as affecting variance and correlations. Variance and correlation effects are often signatures of epistasis or gene-environmental interactions. These complex effects can translate into CAD risk. For example, Trp154Ter in FUT2 protects against CAD among subjects with the A1 blood group, whereas it associates with greater risk of CAD in others. His48Arg in ADH1B interacts with alcohol consumption to affect lipid levels and CAD. The effect of variants in TM6SF2 on blood lipids is greatest among those who never eat oily fish but absent from those who often do. This work demonstrates that variants that affect variance of quantitative traits can allow for the discovery of epistasis and interactions of variants with the environment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37714134</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.012>10.1016/j.cell.2023.08.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714134</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Audunn S Snaebjarnarson</dc:creator>
<dc:creator>Anna Helgadottir</dc:creator>
<dc:creator>Gudny A Arnadottir</dc:creator>
<dc:creator>Erna V Ivarsdottir</dc:creator>
<dc:creator>Gudmar Thorleifsson</dc:creator>
<dc:creator>Egil Ferkingstad</dc:creator>
<dc:creator>Gudmundur Einarsson</dc:creator>
<dc:creator>Gardar Sveinbjornsson</dc:creator>
<dc:creator>Thorgeir E Thorgeirsson</dc:creator>
<dc:creator>Magnus O Ulfarsson</dc:creator>
<dc:creator>Bjarni V Halldorsson</dc:creator>
<dc:creator>Isleifur Olafsson</dc:creator>
<dc:creator>Christian Erikstrup</dc:creator>
<dc:creator>Ole B Pedersen</dc:creator>
<dc:creator>Mette Nyegaard</dc:creator>
<dc:creator>Mie T Bruun</dc:creator>
<dc:creator>Henrik Ullum</dc:creator>
<dc:creator>Søren Brunak</dc:creator>
<dc:creator>Kasper Karmark Iversen</dc:creator>
<dc:creator>Alex Hoerby Christensen</dc:creator>
<dc:creator>Morten S Olesen</dc:creator>
<dc:creator>Jonas Ghouse</dc:creator>
<dc:creator>Karina Banasik</dc:creator>
<dc:creator>DBDS Genomic Consortium</dc:creator>
<dc:creator>Kirk U Knowlton</dc:creator>
<dc:creator>David O Arnar</dc:creator>
<dc:creator>Gudmundur Thorgeirsson</dc:creator>
<dc:creator>Lincoln Nadauld</dc:creator>
<dc:creator>Sisse Rye Ostrowski</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>Hilma Holm</dc:creator>
<dc:creator>Patrick Sulem</dc:creator>
<dc:creator>Kari Stefansson</dc:creator>
<dc:creator>Daniel F Gudbjartsson</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Complex effects of sequence variants on lipid levels and coronary artery disease</dc:title>
<dc:identifier>pmid:37714134</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.012</dc:identifier>
</item>
<item>
<title>TGF-β signaling in health and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>The TGF-β regulatory system plays crucial roles in the preservation of organismal integrity. TGF-β signaling controls metazoan embryo development, tissue homeostasis, and injury repair through coordinated effects on cell proliferation, phenotypic plasticity, migration, metabolic adaptation, and immune surveillance of multiple cell types in shared ecosystems. Defects of TGF-β signaling, particularly in epithelial cells, tissue fibroblasts, and immune cells, disrupt immune tolerance, promote...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4007-4037. doi: 10.1016/j.cell.2023.07.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The TGF-β regulatory system plays crucial roles in the preservation of organismal integrity. TGF-β signaling controls metazoan embryo development, tissue homeostasis, and injury repair through coordinated effects on cell proliferation, phenotypic plasticity, migration, metabolic adaptation, and immune surveillance of multiple cell types in shared ecosystems. Defects of TGF-β signaling, particularly in epithelial cells, tissue fibroblasts, and immune cells, disrupt immune tolerance, promote inflammation, underlie the pathogenesis of fibrosis and cancer, and contribute to the resistance of these diseases to treatment. Here, we review how TGF-β coordinates multicellular response programs in health and disease and how this knowledge can be leveraged to develop treatments for diseases of the TGF-β system.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37714133</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.07.036>10.1016/j.cell.2023.07.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714133</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Joan Massagué</dc:creator>
<dc:creator>Dean Sheppard</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>TGF-β signaling in health and disease</dc:title>
<dc:identifier>pmid:37714133</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.07.036</dc:identifier>
</item>
<item>
<title>Getting an aMPLe grasp on hematopoiesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>Hematopoiesis requires balance between self-renewal of stem cells and differentiation into mature blood cells, orchestrated by pathways such as thrombopoietin signaling. In this issue of Cell, Tsutsumi et al. report the structure of the thrombopoietin ligand-receptor complex and demonstrate the potential to decouple its roles in self-renewal and hematopoietic differentiation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4005-4006. doi: 10.1016/j.cell.2023.08.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hematopoiesis requires balance between self-renewal of stem cells and differentiation into mature blood cells, orchestrated by pathways such as thrombopoietin signaling. In this issue of Cell, Tsutsumi et al. report the structure of the thrombopoietin ligand-receptor complex and demonstrate the potential to decouple its roles in self-renewal and hematopoietic differentiation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37714132</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.015>10.1016/j.cell.2023.08.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714132</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Samantha Joubran</dc:creator>
<dc:creator>Vijay G Sankaran</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Getting an aMPLe grasp on hematopoiesis</dc:title>
<dc:identifier>pmid:37714132</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.015</dc:identifier>
</item>
<item>
<title>Looking beyond the H5 avian influenza viruses</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37714131/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>Avian influenza viruses continue to cross the species barrier and infect mammals. In this issue of Cell, Sun and colleagues demonstrate that viruses obtained from humans infected with an emergent avian H3N8 viruses exhibit increasing accumulation of mutations that promote respiratory droplet transmission and disease in mammals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 14;186(19):4003-4004. doi: 10.1016/j.cell.2023.08.014.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Avian influenza viruses continue to cross the species barrier and infect mammals. In this issue of Cell, Sun and colleagues demonstrate that viruses obtained from humans infected with an emergent avian H3N8 viruses exhibit increasing accumulation of mutations that promote respiratory droplet transmission and disease in mammals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37714131/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37714131</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.014>10.1016/j.cell.2023.08.014</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37714131</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Rebekah Honce</dc:creator>
<dc:creator>Stacey Schultz-Cherry</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Looking beyond the H5 avian influenza viruses</dc:title>
<dc:identifier>pmid:37714131</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.014</dc:identifier>
</item>
<item>
<title>ANGPTL3 Deficiency and Risk of Hepatic Steatosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37712257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in ANGPTL3, as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065866. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ANGPTL3 (angiopoietin-like 3 protein) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of ANGPTL3, reported a dose-dependent increase in hepatic fat. It is unclear whether this adverse effect is due to an on-target effect of inhibiting hepatic ANGPTL3.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The authors recruited participants with ANGPTL3 deficiency related to <i>ANGPTL3</i> loss-of-function (LoF) mutations, along with wild-type (WT) participants from 2 previously characterized cohorts located in Campodimele, Italy, and St. Louis, MO. Magnetic resonance spectroscopy and magnetic resonance proton density fat fraction were performed to measure hepatic fat fraction and the distribution of extrahepatic fat. To estimate the causal relationship between ANGPTL3 and hepatic fat, we generated a genetic instrument of plasma ANGPTL3 levels as a surrogate for hepatic protein synthesis and performed Mendelian randomization analyses with hepatic fat in the UK Biobank study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We recruited participants with complete (n=6) or partial (n=32) ANGPTL3 deficiency related to <i>ANGPTL3</i> LoF mutations, as well as WT participants (n=92) without LoF mutations. Participants with ANGPTL3 deficiency exhibited significantly lower total cholesterol (complete deficiency, 78.5 mg/dL; partial deficiency, 172 mg/dL; WT, 188 mg/dL; <i>P</i>&lt;0.05 for both deficiency groups compared with WT), along with plasma triglycerides (complete deficiency, 26 mg/dL; partial deficiency, 79 mg/dL; WT, 88 mg/dL; <i>P</i>&lt;0.05 for both deficiency groups compared with WT) without any significant difference in hepatic fat (complete deficiency, 7.9%; partial deficiency, 6.4%; WT, 6.9%; <i>P</i>>;0.05 for both deficiency groups compared with WT) or severity of hepatic steatosis as assessed by magnetic resonance imaging. In addition, ANGPTL3 deficiency did not alter the distribution of extrahepatic fat. Results from Mendelian randomization analyses in 36 703 participants from the UK Biobank demonstrated that genetically determined ANGPTL3 plasma protein levels were causally associated with low-density lipoprotein cholesterol (<i>P</i>=1.7×10<sup>-17</sup>) and triglycerides (<i>P</i>=3.2×10<sup>-18</sup>) but not with hepatic fat (<i>P</i>=0.22).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in <i>ANGPTL3</i>, as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37712257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37712257</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065866>10.1161/CIRCULATIONAHA.123.065866</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37712257</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Laura D'Erasmo</dc:creator>
<dc:creator>Michele Di Martino</dc:creator>
<dc:creator>Thomas Neufeld</dc:creator>
<dc:creator>Tyler J Fraum</dc:creator>
<dc:creator>Chul Joo Kang</dc:creator>
<dc:creator>Kendall H Burks</dc:creator>
<dc:creator>Alessia Di Costanzo</dc:creator>
<dc:creator>Ilenia Minicocci</dc:creator>
<dc:creator>Simone Bini</dc:creator>
<dc:creator>Marianna Maranghi</dc:creator>
<dc:creator>Giovanni Pigna</dc:creator>
<dc:creator>Giancarlo Labbadia</dc:creator>
<dc:creator>Jie Zheng</dc:creator>
<dc:creator>Davide Fierro</dc:creator>
<dc:creator>Anna Montali</dc:creator>
<dc:creator>Fabrizio Ceci</dc:creator>
<dc:creator>Carlo Catalano</dc:creator>
<dc:creator>Nicholas O Davidson</dc:creator>
<dc:creator>Giuseppe Lucisano</dc:creator>
<dc:creator>Antonio Nicolucci</dc:creator>
<dc:creator>Marcello Arca</dc:creator>
<dc:creator>Nathan O Stitziel</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>ANGPTL3 Deficiency and Risk of Hepatic Steatosis</dc:title>
<dc:identifier>pmid:37712257</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065866</dc:identifier>
</item>
<item>
<title>Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37712250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065117. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiovascular diseases are the main cause of worldwide morbidity and mortality, highlighting the need for new therapeutic strategies. Autophosphorylation and subsequent overactivation of the cardiac stress-responsive enzyme CaMKIIδ (Ca<sup>2+</sup>/calmodulin-dependent protein kinase IIδ) serves as a central driver of multiple cardiac disorders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To develop a comprehensive therapy for heart failure, we used CRISPR-Cas9 adenine base editing to ablate the autophosphorylation site of CaMKIIδ. We generated mice harboring a phospho-resistant CaMKIIδ mutation in the germline and subjected these mice to severe transverse aortic constriction, a model for heart failure. Cardiac function, transcriptional changes, apoptosis, and fibrosis were assessed by echocardiography, RNA sequencing, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and standard histology, respectively. Specificity toward <i>CaMKIIδ</i> gene editing was assessed using deep amplicon sequencing. Cellular Ca<sup>2+</sup> homeostasis was analyzed using epifluorescence microscopy in Fura-2-loaded cardiomyocytes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Within 2 weeks after severe transverse aortic constriction surgery, 65% of all wild-type mice died, and the surviving mice showed a dramatically impaired cardiac function. In contrast to wild-type mice, CaMKIIδ phospho-resistant gene-edited mice showed a mortality rate of only 11% and exhibited a substantially improved cardiac function after severe transverse aortic constriction. Moreover, CaMKIIδ phospho-resistant mice were protected from heart failure-related aberrant changes in cardiac gene expression, myocardial apoptosis, and subsequent fibrosis, which were observed in wild-type mice after severe transverse aortic constriction. On the basis of identical mouse and human genome sequences encoding the autophosphorylation site of <i>CaMKIIδ</i>, we deployed the same editing strategy to modify this pathogenic site in human induced pluripotent stem cells. It is notable that we detected a >;2000-fold increased specificity for editing of <i>CaMKIIδ</i> compared with other <i>CaMKII</i> isoforms, which is an important safety feature. Although wild-type cardiomyocytes showed impaired Ca<sup>2+</sup> transients and an increased frequency of arrhythmias after chronic β-adrenergic stress, <i>CaMKIIδ</i>-edited cardiomyocytes were protected from these adverse responses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37712250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37712250</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065117>10.1161/CIRCULATIONAHA.123.065117</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37712250</guid>
<pubDate>Fri, 15 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Simon Lebek</dc:creator>
<dc:creator>Xurde M Caravia</dc:creator>
<dc:creator>Francesco Chemello</dc:creator>
<dc:creator>Wei Tan</dc:creator>
<dc:creator>John R McAnally</dc:creator>
<dc:creator>Kenian Chen</dc:creator>
<dc:creator>Lin Xu</dc:creator>
<dc:creator>Ning Liu</dc:creator>
<dc:creator>Rhonda Bassel-Duby</dc:creator>
<dc:creator>Eric N Olson</dc:creator>
<dc:date>2023-09-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice</dc:title>
<dc:identifier>pmid:37712250</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065117</dc:identifier>
</item>
<item>
<title>Semaglutide is beneficial in patients with HFpEF and obesity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37709935/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 14. doi: 10.1038/s41569-023-00935-6. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37709935/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37709935</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00935-6>10.1038/s41569-023-00935-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37709935</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Semaglutide is beneficial in patients with HFpEF and obesity</dc:title>
<dc:identifier>pmid:37709935</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00935-6</dc:identifier>
</item>
<item>
<title>Immunomodulation and immunopharmacology in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37709934/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>The immune system is intimately involved in the pathophysiology of heart failure. However, it is currently underused as a therapeutic target in the clinical setting. Moreover, the development of novel immunomodulatory therapies and their investigation for the treatment of patients with heart failure are hampered by the fact that currently used, evidence-based treatments for heart failure exert multiple immunomodulatory effects. In this Review, we discuss current knowledge on how evidence-based...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 14. doi: 10.1038/s41569-023-00919-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The immune system is intimately involved in the pathophysiology of heart failure. However, it is currently underused as a therapeutic target in the clinical setting. Moreover, the development of novel immunomodulatory therapies and their investigation for the treatment of patients with heart failure are hampered by the fact that currently used, evidence-based treatments for heart failure exert multiple immunomodulatory effects. In this Review, we discuss current knowledge on how evidence-based treatments for heart failure affect the immune system in addition to their primary mechanism of action, both to inform practising physicians about these pleiotropic actions and to create a framework for the development and application of future immunomodulatory therapies. We also delineate which subpopulations of patients with heart failure might benefit from immunomodulatory treatments. Furthermore, we summarize completed and ongoing clinical trials that assess immunomodulatory treatments in heart failure and present several therapeutic targets that could be investigated in the future. Lastly, we provide future directions to leverage the immunomodulatory potential of existing treatments and to foster the investigation of novel immunomodulatory therapeutics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37709934/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37709934</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00919-6>10.1038/s41569-023-00919-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37709934</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>George Markousis-Mavrogenis</dc:creator>
<dc:creator>Lukas Baumhove</dc:creator>
<dc:creator>Ali A Al-Mubarak</dc:creator>
<dc:creator>Joseph Pierre Aboumsallem</dc:creator>
<dc:creator>Nils Bomer</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Immunomodulation and immunopharmacology in heart failure</dc:title>
<dc:identifier>pmid:37709934</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00919-6</dc:identifier>
</item>
<item>
<title>Frataxin Deacetylation in Macrophages: Avoiding SIRTain Myocyte Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37708247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 15;133(7):648-650. doi: 10.1161/CIRCRESAHA.123.323503. Epub 2023 Sep 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37708247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37708247</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323503>10.1161/CIRCRESAHA.123.323503</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37708247</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ronald J Vagnozzi</dc:creator>
<dc:creator>Emma L Robinson</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Frataxin Deacetylation in Macrophages: Avoiding SIRTain Myocyte Death</dc:title>
<dc:identifier>pmid:37708247</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323503</dc:identifier>
</item>
<item>
<title>Resolving Proteotoxicity: Genetic Examination of Proteasome Activation by PKA In Vivo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37708246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 15;133(7):588-591. doi: 10.1161/CIRCRESAHA.123.323502. Epub 2023 Sep 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37708246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37708246</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323502>10.1161/CIRCRESAHA.123.323502</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37708246</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Shirin Doroudgar</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Resolving Proteotoxicity: Genetic Examination of Proteasome Activation by PKA In Vivo</dc:title>
<dc:identifier>pmid:37708246</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323502</dc:identifier>
</item>
<item>
<title>α2δ-1 as a New Target for Immunosuppressant-Induced Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37708245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 15;133(7):628-630. doi: 10.1161/CIRCRESAHA.123.323500. Epub 2023 Sep 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37708245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37708245</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323500>10.1161/CIRCRESAHA.123.323500</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37708245</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Antentor Hinton</dc:creator>
<dc:creator>Annet Kirabo</dc:creator>
<dc:date>2023-09-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>α2δ-1 as a New Target for Immunosuppressant-Induced Hypertension</dc:title>
<dc:identifier>pmid:37708245</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323500</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37708243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 15;133(7):540-541. doi: 10.1161/RES.0000000000000633. Epub 2023 Sep 14.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37708243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37708243</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000633>10.1161/RES.0000000000000633</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37708243</guid>
<pubDate>Thu, 14 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-14</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:37708243</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000633</dc:identifier>
</item>
<item>
<title>Age-induced senescence impairs the neurovascular interface in the heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 13. doi: 10.1038/s41569-023-00936-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37704795</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00936-5>10.1038/s41569-023-00936-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704795</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Harman</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Age-induced senescence impairs the neurovascular interface in the heart</dc:title>
<dc:identifier>pmid:37704795</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00936-5</dc:identifier>
</item>
<item>
<title>Complete revascularization in MI: role in older patients and optimal timing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704794/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 13. doi: 10.1038/s41569-023-00933-8. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704794/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37704794</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00933-8>10.1038/s41569-023-00933-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704794</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Complete revascularization in MI: role in older patients and optimal timing</dc:title>
<dc:identifier>pmid:37704794</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00933-8</dc:identifier>
</item>
<item>
<title>Reply: Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704318/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):e103. doi: 10.1016/j.jacc.2023.06.042.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704318/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37704318</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.042>10.1016/j.jacc.2023.06.042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704318</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>John K Forrest</dc:creator>
<dc:creator>Michael J Reardon</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial</dc:title>
<dc:identifier>pmid:37704318</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.042</dc:identifier>
</item>
<item>
<title>Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704317/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):e101. doi: 10.1016/j.jacc.2023.05.071.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704317/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37704317</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.071>10.1016/j.jacc.2023.05.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704317</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Fabio Barili</dc:creator>
<dc:creator>Amedeo Anselmi</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:creator>Miguel Sousa Uva</dc:creator>
<dc:creator>Alessandro Parolari</dc:creator>
<dc:creator>International Evidence Grading Research Initiative Targeting Transparency and Quality (INTEGRITTY)</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Concerns Regarding the Report of 3-Year Outcomes of the Evolut Low Risk Trial</dc:title>
<dc:identifier>pmid:37704317</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.071</dc:identifier>
</item>
<item>
<title>Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704316/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>Centers specializing in coronary function testing are critical to ensure a systematic approach to the diagnosis and treatment of angina with nonobstructive coronary arteries (ANOCA). Management leveraging lifestyle, pharmacology, and device-based therapeutic options for ANOCA can improve angina burden and quality of life in affected patients. Multidisciplinary care teams that can tailor and titrate therapies based on individual patient needs are critical to the success of comprehensive programs....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1264-1279. doi: 10.1016/j.jacc.2023.06.044.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Centers specializing in coronary function testing are critical to ensure a systematic approach to the diagnosis and treatment of angina with nonobstructive coronary arteries (ANOCA). Management leveraging lifestyle, pharmacology, and device-based therapeutic options for ANOCA can improve angina burden and quality of life in affected patients. Multidisciplinary care teams that can tailor and titrate therapies based on individual patient needs are critical to the success of comprehensive programs. As coronary function testing for ANOCA is more widely adopted, collaborative research initiatives will be fundamental to improve ANOCA care. These efforts will require standardized symptom assessments and data collection, which will propel future large-scale clinical trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704316/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37704316</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.044>10.1016/j.jacc.2023.06.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704316</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Nathaniel R Smilowitz</dc:creator>
<dc:creator>Megha Prasad</dc:creator>
<dc:creator>R Jay Widmer</dc:creator>
<dc:creator>Olga Toleva</dc:creator>
<dc:creator>Odayme Quesada</dc:creator>
<dc:creator>Nadia R Sutton</dc:creator>
<dc:creator>Amir Lerman</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Manoj Kesarwani</dc:creator>
<dc:creator>Michael P Savage</dc:creator>
<dc:creator>Joseph M Sweeny</dc:creator>
<dc:creator>Katherine B Janaszek</dc:creator>
<dc:creator>Ailin Barseghian El-Farra</dc:creator>
<dc:creator>Noa Holoshitz</dc:creator>
<dc:creator>Ki Park</dc:creator>
<dc:creator>Ahmed Albadri</dc:creator>
<dc:creator>John A Blair</dc:creator>
<dc:creator>Allen Jeremias</dc:creator>
<dc:creator>Kathleen E Kearney</dc:creator>
<dc:creator>Yuhei Kobayashi</dc:creator>
<dc:creator>Steven E S Miner</dc:creator>
<dc:creator>Bruce A Samuels</dc:creator>
<dc:creator>Samit M Shah</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Janet Wei</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Jeffery W Moses</dc:creator>
<dc:creator>Timothy D Henry</dc:creator>
<dc:creator>Jennifer A Tremmel</dc:creator>
<dc:creator>Microvascular Network (MVN)</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37704316</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.044</dc:identifier>
</item>
<item>
<title>Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37704315/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230918041107&amp;v=2.17.9.post6+86293ac
      <description>Angina with nonobstructive coronary arteries (ANOCA) is increasingly recognized and may affect nearly one-half of patients undergoing invasive coronary angiography for suspected ischemic heart disease. This working diagnosis encompasses coronary microvascular dysfunction, microvascular and epicardial spasm, myocardial bridging, and other occult coronary abnormalities. Patients with ANOCA often face a high burden of symptoms and may experience repeated presentations to multiple medical providers...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Sep 19;82(12):1245-1263. doi: 10.1016/j.jacc.2023.06.043.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Angina with nonobstructive coronary arteries (ANOCA) is increasingly recognized and may affect nearly one-half of patients undergoing invasive coronary angiography for suspected ischemic heart disease. This working diagnosis encompasses coronary microvascular dysfunction, microvascular and epicardial spasm, myocardial bridging, and other occult coronary abnormalities. Patients with ANOCA often face a high burden of symptoms and may experience repeated presentations to multiple medical providers before receiving a diagnosis. Given the challenges of establishing a diagnosis, patients with ANOCA frequently experience invalidation and recidivism, possibly leading to anxiety and depression. Advances in scientific knowledge and diagnostic testing now allow for routine evaluation of ANOCA noninvasively and in the cardiac catheterization laboratory with coronary function testing (CFT). CFT includes diagnostic coronary angiography, assessment of coronary flow reserve and microcirculatory resistance, provocative testing for endothelial dysfunction and coronary vasospasm, and intravascular imaging for identification of myocardial bridging, with hemodynamic assessment as needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37704315/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230918041107&v=2.17.9.post6+86293ac">37704315</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.043>10.1016/j.jacc.2023.06.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37704315</guid>
<pubDate>Wed, 13 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Bruce A Samuels</dc:creator>
<dc:creator>Samit M Shah</dc:creator>
<dc:creator>R Jay Widmer</dc:creator>
<dc:creator>Yuhei Kobayashi</dc:creator>
<dc:creator>Steven E S Miner</dc:creator>
<dc:creator>Viviany R Taqueti</dc:creator>
<dc:creator>Allen Jeremias</dc:creator>
<dc:creator>Ahmed Albadri</dc:creator>
<dc:creator>John A Blair</dc:creator>
<dc:creator>Kathleen E Kearney</dc:creator>
<dc:creator>Janet Wei</dc:creator>
<dc:creator>Ki Park</dc:creator>
<dc:creator>Ailin Barseghian El-Farra</dc:creator>
<dc:creator>Noa Holoshitz</dc:creator>
<dc:creator>Katherine B Janaszek</dc:creator>
<dc:creator>Manoj Kesarwani</dc:creator>
<dc:creator>Amir Lerman</dc:creator>
<dc:creator>Megha Prasad</dc:creator>
<dc:creator>Odayme Quesada</dc:creator>
<dc:creator>Harmony R Reynolds</dc:creator>
<dc:creator>Michael P Savage</dc:creator>
<dc:creator>Nathaniel R Smilowitz</dc:creator>
<dc:creator>Nadia R Sutton</dc:creator>
<dc:creator>Joseph M Sweeny</dc:creator>
<dc:creator>Olga Toleva</dc:creator>
<dc:creator>Timothy D Henry</dc:creator>
<dc:creator>Jeffery W Moses</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>Jennifer A Tremmel</dc:creator>
<dc:creator>Microvascular Network (MVN)</dc:creator>
<dc:date>2023-09-13</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37704315</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.043</dc:identifier>
</item>





























</channel>
</rss>